Lupin’s journey is a testament to the potential of human imagination, compassion, and the unwavering pursuit of a better tomorrow. Established in 1968 by our visionary founder, Dr. Desh Bandhu Gupta, Lupin has evolved from humble beginnings to become a global healthcare leader. Headquartered in Mumbai, India, we have expanded our footprint across the U.S., LATAM, APAC and EMEA regions, operating in over 100 countries and offering a diverse portfolio of over 1,000 products.
Inspired by the resilient lupin flower that nourishes the soil while thriving in challenging conditions, Lupin remains committed to its mission of making quality healthcare accessible to all. We recognize the importance of nurturing the communities we serve and leaving a positive impact on society.
With our robust manufacturing capabilities and strong research and development, we have emerged amongst the leaders in generics, complex generics, APIs, specialty, and biologics. Lupin’s commitment to innovation and patient-centricity has fueled its success in therapeutic areas such as cardiovascular health, tuberculosis, diabetes, respiratory, gastrointestinal disorders, and women’s health.
At Lupin, we understand that true success lies in the convergence of business growth and social impact. Beyond healthcare, we are dedicated to the upliftment of the communities we serve. This commitment is channeled through the Lupin Human Welfare and Research Foundation (LHWRF), which focuses on two pillars: Improving Lives and Improving Livelihood. Across 5,431 villages in nine states of India, we positively impact the lives of over 2.5 Mn people, reflecting our commitment to social responsibility and sustainable change.
Our journey is guided by the belief that healthcare should be accessible, affordable, and of the highest quality. We strive to advance our infrastructure, embrace innovation, and expand our presence in high-growth markets to better serve the evolving needs of patients worldwide.
As we embark on the next chapter of our story, we remain committed to our vision, mission, and core values. With boundless optimism, we embrace the challenges that lie ahead, confident that our collective efforts will continue to make a lasting impact on the world of healthcare.
We empower our employees to generate new ideas, explore avenues and offer solutions that add exceptional value.
We encourage them to build ownership in all endeavours by assuming responsibility with passion and conviction.
We conduct ourselves with uncompromising integrity and honesty with the highest standards of ethical behaviour and transparency.
Everything we do must stand public scrutiny.
We are compassionate and sensitive towards all our stakeholders and treat them the way we would expect to be treated.
We provide equal and fair opportunities for employment, learning and career development.
We relentlessly pursue excellence through innovation and continuous improvement in all our projects, processes and products.
To set our standards, we benchmark with the best in the world.
We strive to understand and meet customer needs in a professional and responsive manner.
We focus on building long-term partnerships for mutual benefit.
We align our efforts and energies of our people across all levels and geographies to deliver outstanding results to our stakeholders.
We encourage diverse opinions and yet work together in a coordinated and mutually supportive way.
We are poised to extend our leadership in key markets, India and the U.S., through a comprehensive strategy
that fuels growth, innovation, and portfolio evolution in complex generics.
In India, we aim to outpace the market by strategically expanding our presence in existing therapeutic areas
while exploring newer domains. Leveraging our extensive network, we are making significant strides in
adjacencies such as Diagnostics, Digital Therapeutics solutions, and Neurorehabilitation. Our steadfast focus
on chronic therapies, which contribute 62.5% of our domestic branded formulation revenues, has laid the
foundation for substantial growth in areas like Cardiovascular, Diabetes, and Respiratory treatments.
READ MORE
Lupin's commitment to building a sustainable future is at the core of our long-term value creation strategy.
In FY23, we made significant strides in our ESG agenda, setting the stage for transformative initiatives that
lie ahead.
Environmental Impact: We completed a comprehensive Scope 3 greenhouse gas emissions assessment, furthering our
understanding of our carbon footprint. To drive cleaner energy practices, we are expanding our renewable
capacity by over 22 MW in FY24, bringing our total capacity to over 36 MW. This substantial investment
underscores our dedication to reducing our carbon emissions and embracing sustainable energy sources.
READ MORE
Lupin remains committed to enhancing the efficiency and productivity of our R&D and manufacturing network
through targeted cost and resource optimization initiatives. By optimizing capital expenditure and R&D spends,
we leverage our portfolio across markets with similar regulatory regimes, unlocking further efficiencies.
To drive resource efficiencies, we prioritize key initiatives such as developing alternate/new routes of
synthesis and implementing process improvements. Our cost optimization strategy encompasses operating leverage
across manpower productivity, sales force excellence, and the establishment of Centers of Excellence for
support services. Embracing digital transformation, we have embarked on various initiatives across the value
chain, anticipating substantial dividends in the future.
READ MORE
With continued pricing and competitive pressure on oral solids, we believe that it is critical to expand our
basket of first-to-market opportunities and increase our offerings on complex dosage forms like injectables,
inhalation and biosimilars. By venturing beyond oral solids, we aim to capture new market share, address unmet
medical needs, and maximize value creation.
Inhalation: Lupin’s remarkable achievement as one of the few companies worldwide to obtain approval for
generic versions of both Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) in the U.S. and EU markets
demonstrates our commitment to pioneering advancements. Building on this success, we have filed multiple
inhalation products and are actively developing an expansive pipeline.
READ MORE
With continued pricing and competitive pressure on oral solids, we believe that it is critical to expand our
basket of first-to-market opportunities and increase our offerings on complex dosage forms like injectables,
inhalation and biosimilars. By venturing beyond oral solids, we aim to capture new market share, address unmet
medical needs, and maximize value creation.
Inhalation: Lupin’s remarkable achievement as one of the few companies worldwide to obtain approval for
generic versions of both Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) in the U.S. and EU markets
demonstrates our commitment to pioneering advancements. Building on this success, we have filed multiple
inhalation products and are actively developing an expansive pipeline.
READ MORE
Vinita Gupta, named among India's 20 Most Influential Women in Healthcare by BW Healthcare World
Rajendra Chunodkar named among the Game Changers in Manufacturing by Fortune India
‘Factories of the Future’ accoladeat the Economic Times Promising Plant Awards 2022
Marketing Campaign Of The Year by ET India Pharmaworld Awards for its Awareness, Screening, and Treatment (AST) Campaign
Bioprocessing Excellence in South Asia Award at the prestigious Asia Pacific Bioprocessing Excellence Awards 2022 by IMAPAC
Team Pithampur won four awards at 43rd CII National Kaizen Competition
LHWRF won the Water Sustainability Awards 2022-23 for Excellence in Participatory Water Management
Excellence in Patient Centric Initiative at Zee Health Awards 2022
Lupin Ankleshwar won the Par Excellence Award for Ethambutol Yield Improvement Project and Excellent Award for 7ACCA Yield Improvement Project in the Lean Six Sigma Category
Business World’s Diversity and Inclusion Award 2022 for “Outstanding DiversityNetwork”
Cyber Security Excellence Awards 2022 for the Best Zero Security in the Healthcare & Pharma category
Goa and Nagpur teams have been awarded Gold Medal at the National Awards for Manufacturing Competitiveness 2022-23
ATD (Association of Talent Development) BEST Award
Dabhasa Site Recognized in the silver category at the India Green Manufacturing Challenge 2021-22 organized by International Research Institute for Manufacturing
‘Digital Pharma Marketing Excellence Award’ for ‘Leveraging Technology for Patient Care’ at the 6th Edition of DIGIPHARMAX Conclave on Emerging Health Trends in Pharma Digital Marketing & Awards 2022
Softovac recognized as Epitome of New-Age Success at the Most Preferred Brands 2022 Event
Global Supply Chain & Operations (GSCO) team won the ‘Apex 10 Supply Chains (West)’ award at the Top 200 Supply Chains Awards (West), organized by the Alden Group
Lupin Diagnostics Bags the Award for Best Pathology Lab (National Category) at The Economic Times ET Healthcare Awards 2022
Team Goa won First prize and one platinum award at 16th CII Six Sigma National Level Competition 2022
Team Goa and Team Nagpur Unit-1 received the Gold Medal at National Awards for Manufacturing Competitiveness 2022-23
Lupin’s Pithampur team wins two awards - 1 Platinum, and 1 Gold at the CII National Technology Competition
Lupin’s corporate communication team named among the Top 30 Corporate Communications Team for 2022 by Reputation Today
Assurance Statement